HDAC6 and neoplasm: reported that MS-275, an inhibitor of HDAC1-3, reduced the immunosuppressive activity of PMN-MDSCs, whereas ricolinostat, an inhibitor of HDAC6, reduced the immunosuppressive activity of M-MDSCs in tumor-bearing mice [16].